189 related articles for article (PubMed ID: 33245517)
1. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
2. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.
Byeon JY; Kim YH; Na HS; Jang JH; Kim SH; Lee YJ; Bae JW; Kim IS; Jang CG; Chung MW; Lee SY
Arch Pharm Res; 2015 Nov; 38(11):2083-91. PubMed ID: 26254792
[TBL] [Abstract][Full Text] [Related]
3. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.
Belle DJ; Ernest CS; Sauer JM; Smith BP; Thomasson HR; Witcher JW
J Clin Pharmacol; 2002 Nov; 42(11):1219-27. PubMed ID: 12412820
[TBL] [Abstract][Full Text] [Related]
4. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.
Choi CI; Bae JW; Lee YJ; Lee HI; Jang CG; Lee SY
J Clin Psychopharmacol; 2014 Feb; 34(1):139-42. PubMed ID: 24346747
[TBL] [Abstract][Full Text] [Related]
6. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
[TBL] [Abstract][Full Text] [Related]
7. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.
Kim SH; Byeon JY; Kim YH; Lee CM; Lee YJ; Jang CG; Lee SY
Sci Rep; 2018 Aug; 8(1):12405. PubMed ID: 30120390
[TBL] [Abstract][Full Text] [Related]
9. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.
Dinh JC; Pearce RE; Van Haandel L; Gaedigk A; Leeder JS
Drug Metab Dispos; 2016 Jul; 44(7):1070-9. PubMed ID: 27052878
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
Bae JW; Oh KY; Yoon SJ; Shin HB; Jung EH; Cho CK; Lim CW; Kang P; Choi CI; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
[TBL] [Abstract][Full Text] [Related]
12. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
14. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Paulzen M; Clement HW; GrĂ¼nder G
Int J Neuropsychopharmacol; 2008 Mar; 11(2):289-91. PubMed ID: 18215333
[No Abstract] [Full Text] [Related]
16. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
17. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite.
Todor I; Popa A; Neag M; Muntean D; Bocsan C; Buzoianu A; Vlase L; Gheldiu AM; Chira R; Briciu C
Clujul Med; 2015; 88(4):513-20. PubMed ID: 26733750
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.
Matsui A; Azuma J; Witcher JW; Long AJ; Sauer JM; Smith BP; DeSante KA; Read HA; Takahashi M; Nakano M
J Clin Pharmacol; 2012 Mar; 52(3):388-403. PubMed ID: 21543662
[TBL] [Abstract][Full Text] [Related]
19. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
Witcher JW; Long A; Smith B; Sauer JM; Heilgenstein J; Wilens T; Spencer T; Biederman J
J Child Adolesc Psychopharmacol; 2003; 13(1):53-63. PubMed ID: 12804126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]